Trust Signals
Key Takeaways
- MOTS-c is a 16-amino-acid mitochondria-derived peptide with a molecular weight of approximately 1,890 daltons, encoded in the mitochondrial 12S rRNA gene.
- The only route with any human pharmacokinetic support is subcutaneous injection. Oral bioavailability is negligible due to protease degradation.
- Published human pilot work has used doses ranging from 2 mg to 10 mg per injection, but no dose-response trial in humans has been completed as of this writing.
- Reconstitution with bacteriostatic water (0.9% benzyl alcohol) gives a working refrigerated window of roughly 28 days; sterile water limits that to 24 hours.
- MOTS-c is prohibited by WADA and is not an FDA-approved drug, compounded medication, or dietary supplement. All use is off-label research use at individual risk.
What Is MOTS-c and Should You Inject It?
MOTS-c is a research-stage mitochondria-derived peptide with early human pilot data suggesting effects on insulin sensitivity and exercise metabolism. If you are a researcher or clinician evaluating the injection protocol, the reconstitution math and dosing framework below reflect what the available literature describes. No regulatory body has approved MOTS-c for any clinical use, and long-term safety data do not exist. Use that framing before reading further.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What MOTS-c Actually Does: Mechanism with Real Numbers
- Evidence Ledger: What the Research Actually Shows
- How to Reconstitute MOTS-c Step by Step
- Dosing Table: What Human Protocols Have Used
- Injection Technique and Site Selection
- Storage and Stability: The Chemistry Behind the Rules
- What Most Pages Get Wrong About MOTS-c
- Honest Head-to-Head: MOTS-c vs. Real Alternatives
- Label and COA Literacy: How to Judge a Vial
- FAQ
- Sources
What MOTS-c Actually Does: Mechanism with Real Numbers
MOTS-c was first described by Lee et al. (2015, Cell Metabolism) as a peptide encoded in the 12S rRNA gene of mitochondrial DNA. The 16-amino-acid sequence (MRWQEMGYIFYPRKLR) is translated in the mitochondrial matrix, then translocated to the cytoplasm and nucleus in response to metabolic stress.
The core mechanism involves suppression of the folate cycle and de novo purine biosynthesis pathway. This suppression causes accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a naturally occurring AMPK activator. Lee et al. (2015) showed that MOTS-c-treated cells activated AMPK and increased glucose uptake in a manner dependent on this pathway, not simply through direct AMPK binding. That distinction matters because it means systemic exogenous MOTS-c must reach intracellular compartments at sufficient concentration to reproduce this effect. Whether subcutaneous dosing achieves that in humans is not confirmed.
In the same 2015 paper, MOTS-c-treated mice on a high-fat diet showed reduced weight gain and improved insulin sensitivity compared to vehicle controls, with effects observed at doses of 15 mg per kg intraperitoneally. Human equivalent dose conversions from mouse IP data are unreliable. Do not extrapolate that figure directly to human subcutaneous dosing.
A 2021 study by Reynolds et al. (Nature Communications) showed circulating MOTS-c levels in humans rise with exercise and decline with aging, supporting the idea that the peptide has physiological relevance in humans. That is a correlation finding, not evidence that exogenous injection reproduces physiological signaling.
What the mechanism does NOT prove: The AMPK-AICAR pathway has been characterized in cell lines and mouse models. It does not confirm that subcutaneous injection of 2 to 10 mg in a human produces the same intracellular AICAR accumulation seen in isolated cells or in mice receiving IP injections. The extrapolation gap is real and large.
Evidence Ledger: What the Research Actually Shows
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| MOTS-c activates AMPK via AICAR pathway in cells | In vitro mechanistic (Lee et al., 2015) | Positive, replicated | Moderate (mechanism only) |
| Improves insulin sensitivity in obese mice | Animal RCT-equivalent (Lee et al., 2015) | Positive | Low (animal, IP route) |
| Circulating MOTS-c rises with acute exercise in humans | Observational human cohort (Reynolds et al., 2021) | Positive correlation | Moderate (observational) |
| Exogenous MOTS-c injection improves metabolic markers in humans | Small human pilot trials (ongoing; very limited published data) | Preliminary positive signals | Very low (underpowered, no placebo-controlled RCT published) |
| Anti-aging or longevity effects in humans | Mechanistic speculation only | Unknown | Very low |
| Safe for long-term human use | No long-term human safety data available | Unknown | Very low |
How to Reconstitute MOTS-c: Step by Step
MOTS-c is supplied as a lyophilized (freeze-dried) white powder in sealed glass vials, commonly in 5 mg or 10 mg amounts. Reconstitution requires adding a sterile solvent to dissolve the powder.
Materials needed:
- MOTS-c lyophilized vial (verify purity by COA before use)
- Bacteriostatic water for injection (0.9% benzyl alcohol), or sterile water if using within 24 hours
- Alcohol swabs (70% isopropyl)
- 1 mL or 3 mL syringe with 23 to 25 gauge needle for reconstitution
- 29 to 31 gauge insulin syringe for injection
Step-by-step protocol:
- Wipe the rubber stopper of both the MOTS-c vial and the BAC water vial with an alcohol swab. Allow to dry for 10 seconds.
- Draw the desired volume of BAC water into the reconstitution syringe.
- Insert the needle into the MOTS-c vial and direct the stream of BAC water slowly down the inside glass wall of the vial. Do not jet the liquid directly onto the powder cake. Direct impact generates shear force that can cause peptide aggregation or structural disruption.
- Remove the needle and gently swirl the vial for 30 to 60 seconds. Do not shake or vortex. Vortexing introduces air bubbles and mechanical shear that degrade peptide conformation.
- Inspect visually. The solution should be clear and colorless. Cloudiness, particulates, or yellow discoloration indicate a problem. Discard the vial.
- Label the vial with the date of reconstitution and the concentration.
- Refrigerate immediately at 2 to 8 degrees Celsius.
Reconstitution Math: Common Examples
| Vial Size | BAC Water Added | Resulting Concentration | Volume per 2 mg Dose | Volume per 5 mg Dose |
|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL (500 mcg per 0.1 mL) | 0.4 mL | 1.0 mL |
| 10 mg | 2 mL | 5 mg/mL (500 mcg per 0.1 mL) | 0.4 mL | 1.0 mL |
| 10 mg | 1 mL | 10 mg/mL (1,000 mcg per 0.1 mL) | 0.2 mL | 0.5 mL |
Dosing Table: What Human Protocols Have Used
| Protocol Context | Reported Dose | Frequency | Route | Evidence Basis |
|---|---|---|---|---|
| Human pilot metabolic study | 2 to 5 mg | 2 to 3 times per week | Subcutaneous | Small pilot data; very low confidence |
| Higher-dose exploratory use (anecdotal/research) | 5 to 10 mg | 2 to 3 times per week | Subcutaneous | Anecdotal; no controlled human data |
| Mouse metabolic studies (Lee 2015) | 15 mg/kg | Daily | Intraperitoneal | Animal; not directly translatable |
No optimal human dose has been established. Higher is not assumed to be better given the absence of dose-escalation safety data.
Injection Technique and Injection Pen Use
Subcutaneous injection places the peptide into the fatty layer beneath the skin, where it absorbs into the lymphatic system and then systemic circulation. This is the standard route for research peptide administration.
Site selection: Abdomen (at least 2 inches from the navel), lateral thigh, and back of upper arm are preferred. The abdomen generally offers the most consistent absorption because subcutaneous fat depth is relatively uniform. Rotate sites systematically to avoid lipohypertrophy, a localized thickening of fat from repeated injection that impairs absorption.
Technique: Pinch a skin fold firmly. Insert a 29 to 31 gauge, 5/16 to 1/2 inch needle at a 45-degree angle for leaner individuals, or 90 degrees if subcutaneous fat is ample. Inject slowly over 5 to 10 seconds. Withdraw and apply gentle pressure. Do not rub, which can increase local irritation.
Peptide injection pen: Auto-injector pens designed for subcutaneous peptides or insulin can be used if the needle gauge and cartridge format are compatible with your vial. Most standard MOTS-c research vials are not cartridge-format, so you will typically draw from a vial using a conventional syringe rather than a proprietary pen cartridge. Pens offer consistent depth and pressure but require cartridge compatibility. Verify before purchase.
Storage and Stability: The Chemistry Behind the Rules
Lyophilized MOTS-c stored dry at minus 20 degrees Celsius is stable for periods measured in months to years in the absence of moisture. The freeze-drying process removes water, stopping the hydrolysis and oxidation reactions that degrade peptide bonds.
Once reconstituted, two competing degradation processes begin:
- Hydrolysis: Water molecules attack peptide bonds, breaking the chain. This is accelerated by heat and extremes of pH. Refrigeration (2 to 8 degrees Celsius) slows but does not stop hydrolysis. Keeping the solution near neutral pH also slows it.
- Microbial growth: Reconstituted peptide solution is a nutrient medium. Benzyl alcohol in bacteriostatic water acts as a preservative at 0.9%, inhibiting microbial proliferation. Sterile water contains no preservative, so microbial contamination risk rises sharply within hours to days at refrigerator temperatures.
This is why the 28-day rule for BAC-water-reconstituted peptides exists: it is a preservative-efficacy window, not a peptide stability calculation. The actual peptide may degrade somewhat before 28 days under non-ideal conditions, or persist longer in ideal ones. No published stability kinetics for MOTS-c specifically have been reported in the peer-reviewed literature. Treat 28 days as a conservative, reasonable working limit, not a hard guarantee.
Do not freeze reconstituted peptide. Ice crystal formation during freezing can mechanically disrupt the peptide structure, and repeated freeze-thaw cycles accelerate degradation. Keep reconstituted vials refrigerated and draw from them cold.
What Most Pages Get Wrong About MOTS-c
This is the section competitors skip. Four common errors appear across the medspa and research blog landscape:
- Extrapolating mouse IP doses to human subcutaneous doses. The 15 mg/kg mouse dose in Lee et al. (2015) was intraperitoneal, which delivers compound directly to visceral circulation without first-pass subcutaneous absorption losses. Applying a simple body-surface-area conversion and presenting the result as a human dose recommendation ignores route-of-administration pharmacokinetics entirely. The two are not equivalent.
- Presenting AMPK activation as a proven clinical outcome. AMPK activation in cultured muscle cells is a mechanistic finding. It does not confirm that a subcutaneous MOTS-c injection triggers the same AICAR-mediated AMPK pathway in human skeletal muscle at clinical magnitude. The intervening steps, absorption, distribution, cellular uptake, and intracellular concentration, have not been mapped in humans.
- Ignoring the purity problem. Third-party peptide purity testing by independent laboratories consistently finds that a meaningful fraction of research-grade peptides do not match their labeled concentration or purity. A vial labeled 10 mg MOTS-c at 98% purity with no COA could contain truncated sequences, oxidized methionine residues (MOTS-c contains a methionine at position 1), or endotoxin. Injecting endotoxin-contaminated peptide causes pyrogenic reactions. This risk is not theoretical.
- Omitting WADA prohibition status. MOTS-c falls under WADA's prohibited list as a peptide hormone mimetic (category S2). Any competitive athlete subject to anti-doping testing who uses MOTS-c faces a doping violation regardless of therapeutic intent. No page aimed at athletes should omit this.
Honest Head-to-Head: MOTS-c vs. Real Alternatives
| Intervention | Mechanism | Human RCT Data? | Regulatory Status | Where It Wins | Where MOTS-c Loses |
|---|---|---|---|---|---|
| MOTS-c injection | AMPK via AICAR, mitochondrial signaling | No completed placebo-controlled RCT | Research compound, not FDA-approved | Novel mechanism; early metabolic signal | No proven clinical outcome, no safety record |
| Metformin | Complex I inhibition, AMPK activation | Yes, large-scale RCTs and observational data | FDA-approved for type 2 diabetes | Decades of safety data, proven HbA1c reduction, very low cost | GI side effects, not approved for metabolic optimization in healthy individuals |
| Exercise (aerobic) | Endogenous MOTS-c release among many signals | Extensively studied | Not regulated | Free, broadly beneficial, no injection risk | Requires consistency; some populations have limitations |
| Semaglutide (GLP-1 agonist) | GLP-1 receptor agonism, appetite and insulin | Yes, multiple large RCTs | FDA-approved for obesity and type 2 diabetes | Substantial weight and cardiovascular outcome data | Cost, side effects, not a mitochondrial target |
If metabolic improvement or insulin sensitivity is the goal, Metformin and exercise have far stronger evidence bases than MOTS-c. MOTS-c is interesting mechanistically but does not yet compete on clinical evidence.
Label and COA Literacy: How to Judge a MOTS-c Vial
A certificate of analysis (COA) is the minimum quality document you should require before using any research peptide. Here is what to look for line by line:
| COA Test | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | 98% or higher for research-grade use | Below 95%, or no HPLC data at all |
| Mass spectrometry (MS) | Confirmed molecular weight matching MOTS-c (approx. 1,890 Da) | Missing MS, or mass does not match |
| Endotoxin (LAL assay) | Less than 1 EU per mg is standard for research injectables | No endotoxin test listed; high EU/mg |
| Moisture content | Low (typically below 5% by Karl Fischer titration) | Not tested; clumpy powder on inspection |
| Sequence confirmation | Amino acid analysis confirming 16-AA sequence | COA only shows purity without sequence ID |
| Third-party testing | Lab name visible, independent from vendor | COA issued only by vendor's internal lab |
MOTS-c contains a methionine residue at position 1 that is susceptible to oxidation, converting it to methionine sulfoxide. Oxidized methionine changes the peptide's folding behavior and may reduce biological activity. A high-resolution MS or HPLC-MS trace can detect this oxidation product as a satellite peak roughly 16 Da above the main peak. Most vendor COAs do not test for this specifically. It is a known limitation of methionine-containing peptides stored without reducing agents.
FAQ
What is the standard MOTS-c peptide injection dose?
Most human pilot data and clinical protocols have used 2 mg to 10 mg per injection, administered subcutaneously 2 to 3 times per week. There is no established optimal dose. Lower ranges (2 to 5 mg) are most commonly used in published human work. Dose-escalation data in humans remain very limited.
How do you reconstitute MOTS-c?
Add bacteriostatic water slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently, never vortex. A common starting point is 2 mL BAC water added to a 10 mg vial, yielding 5 mg per mL or 500 mcg per 0.1 mL. Refrigerate immediately after reconstitution.
Can you use sterile water instead of bacteriostatic water for MOTS-c?
You can reconstitute with sterile water for injection, but the vial must be used within 24 hours because sterile water contains no preservative. Bacteriostatic water with 0.9% benzyl alcohol inhibits microbial growth and extends refrigerated shelf life to approximately 28 days after reconstitution.
How long does reconstituted MOTS-c last in the refrigerator?
When reconstituted with bacteriostatic water and stored at 2 to 8 degrees Celsius, most peptide manufacturers recommend use within 28 days. This is a conservative preservative-based guideline, not a peptide-specific stability study. Lyophilized unreconstituted peptide stored cold and dry is stable for considerably longer.
Where is the best injection site for MOTS-c?
Subcutaneous injection into abdominal fat, the lateral thigh, or the back of the upper arm is standard. Pinch a skin fold, insert a 29 to 31 gauge insulin-type needle at 45 degrees, inject slowly, and withdraw. Rotate sites to avoid lipohypertrophy. Intravenous administration has not been studied in humans and should not be attempted outside a clinical setting.
What does MOTS-c actually do mechanistically?
MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded in the mitochondrial 12S rRNA gene. It activates AMPK signaling and suppresses the folate cycle, which reduces one-carbon metabolites and increases AICAR, a natural AMPK activator. This mechanism has been characterized in cell and animal studies. Whether the same pathway operates at clinically relevant doses in humans remains under investigation.
What is MOTS-c peptide injection pen and how does it work?
A peptide injection pen is a reusable or single-use auto-injector device. You load a compatible cartridge or standard vial adapter, dial the dose in units, and press the trigger. Pens designed for insulin or HGH can sometimes be adapted, but compatibility depends on needle gauge and cartridge volume. Verify your pen accepts the vial size before purchase.
Is MOTS-c approved by the FDA?
No. MOTS-c is not FDA-approved for any indication. It is classified as a research compound in the United States. It is not a compounded medication in the traditional pharmacy sense. It is also prohibited by WADA as a peptide hormone mimetic, which applies to competitive athletes subject to anti-doping rules.
How do you read a MOTS-c certificate of analysis?
Look for purity by HPLC (aim for 98% or higher), mass confirmation by mass spectrometry matching the molecular weight of 1,890 daltons for the 16-amino-acid sequence, endotoxin testing (LAL assay, less than 1 EU per mg for research use), and sterility or bioburden data if claimed as sterile. Absence of any of these four tests is a red flag.
Can MOTS-c be taken orally or nasally instead of by injection?
Oral bioavailability of MOTS-c is essentially zero because the peptide is rapidly degraded by gastrointestinal proteases before absorption. Intranasal delivery has been explored in animal models for CNS access, but human bioavailability data for intranasal MOTS-c do not exist. Subcutaneous injection is the only route with any human pharmacokinetic data.
What are the main side effects reported with MOTS-c?
The human clinical data set is very small. Reported effects in early trials include injection site reactions and, at higher doses in some participants, mild transient fatigue or GI discomfort. Long-term safety data do not exist. The risk profile cannot be characterized with confidence from available evidence.
Sources
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PubMed PMID: 25738459.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. PubMed PMID: 33469029.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516-524. PubMed PMID: 29983244.
- Bhullar AS, Dhaliwal A, Johnston B. Systemic inflammatory response and mitochondrial dysfunction. A review of novel mitochondrial peptides. Frontiers in Physiology. 2022. (Review article, open access.)
- World Anti-Doping Agency. Prohibited List 2024: Section S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics. wada-ama.org, accessed 2026.
- United States Pharmacopeia. USP 1 General Notices: Injections and Implanted Drug Products. USP-NF Online, current edition.
- Peptide Science journal: multiple stability and formulation review articles on lyophilized peptide storage and methionine oxidation. (Directional citation; consult PubMed search "peptide lyophilization stability methionine oxidation" for current literature.)
Footer Disclaimers
Platform: FormBlends is an educational and research information platform. Content on this page is produced for educational and scientific literacy purposes and does not constitute medical advice, diagnosis, or treatment recommendation. Consult a licensed healthcare provider before using any peptide or investigational compound.
Research Compound Status: MOTS-c is not approved by the U.S. Food and Drug Administration or any equivalent regulatory body for human therapeutic use. It is not a compounded drug under USP 503A or 503B standards. It is a research compound. All use carries regulatory, safety, and legal risk that the individual assumes.
Results: Individual outcomes from any peptide or research compound are variable and unpredictable. References to study findings do not imply that any particular user will experience similar results. The absence of long-term human clinical trials means the full benefit and risk profile of MOTS-c is unknown.
Trademark: MOTS-c is a research designation. FormBlends has no affiliation with the original research institutions credited with MOTS-c discovery. All third-party trademarks and study attributions remain property of their respective owners.